APA (7th ed.) Citation

A, A., MA, B., J, G., MS, C., PA, A., M, B., . . . GV, L. (2025). Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma. Annals of oncology : official journal of the European Society for Medical Oncology, 36(12), 1535. https://doi.org/10.1016/j.annonc.2025.08.008

Chicago Style (17th ed.) Citation

A, Arance, et al. "Randomized, Double-blind, Phase III LEAP-003 Study of First-line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic Melanoma." Annals of Oncology : Official Journal of the European Society for Medical Oncology 36, no. 12 (2025): 1535. https://doi.org/10.1016/j.annonc.2025.08.008.

MLA (9th ed.) Citation

A, Arance, et al. "Randomized, Double-blind, Phase III LEAP-003 Study of First-line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic Melanoma." Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 36, no. 12, 2025, p. 1535, https://doi.org/10.1016/j.annonc.2025.08.008.